



Singapore Journal of
Scientific Research

ISSN: 2010-006x

science
alert

<http://scialert.net/sjsr>



Research Article

An Improved Antibacterial Activity of Cephalosporin Analogues by Introducing Sulfamoylamino Group

¹Xudong Jiang, ¹Li Chen, ¹Xiaoling Lu, ¹Lan Liao, ¹Xin Zhang, ¹Yuxuan Chen and ²Xiaocheng Huang

¹School of Medicine, Guangxi University of Science and Technology, Liuzhou, China

²College of Biological and Chemical Engineering, Guangxi University of Science and Technology, 545005 Liuzhou, China

Abstract

Background and Objective: Antibiotic resistance is increasing globally because of the widespread use of antibiotics. Therefore, there is an urgent need to find new antibiotics with novel structures and more potent activities. This study was aimed to evaluate the antibacterial activity of cephalosporin analogues by introducing a sulfamoylamino group, displayed the relation between the structure and antibacterial activity. **Materials and Methods:** A series of novel cephalosporin analogues were synthesized and the *in vitro* antibacterial activity against Gram-positive bacteria (*S. aureus*, *S. pneumonia* and *S. epidermidis*) and Gram-negative bacteria (*E. coli*, *P. aeruginosa* and *K. pneumonia*) were performed by the standard agar dilution method. **Results:** The synthesized sulfamoylamino-containing cephalosporin analogues exhibited significantly antibacterial activity against the test bacteria. **Conclusion:** The screening result discovered that sulfamoylamino-containing cephalosporin analogues was able to significantly improved the antibacterial activity, which provided us evidence for the further development of potential cephalosporin antibiotics.

Key words: Antibiotics, bacterial resistance, sulfamoylamino group, cephalosporin, antibacterial activity

Citation: Xudong Jiang, Li Chen, Xiaoling Lu, Lan Liao, Xin Zhang, Yuxuan Chen and Xiaocheng Huang, 2020. An improved antibacterial activity of cephalosporin analogues by introducing sulfamoylamino group. Singapore J. Sci. Res., 10: 123-127.

Corresponding Author: Xiaoling Lu, School of Medicine, Guangxi University of Science and Technology, Liuzhou, China

Copyright: © 2020 Xudong Jiang *et al.* This is an open access article distributed under the terms of the creative commons attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Competing Interest: The authors have declared that no competing interest exists.

Data Availability: All relevant data are within the paper and its supporting information files.

INTRODUCTION

Antibiotics are one of the most effective drug to eliminate or control infectious diseases. In 1940, penicillin was put into use in clinical as the world's first antibiotic¹. After 80 years of the development, antibiotics have saved millions of lives². β -lactam antibiotics is a breeding fungicides and there are no cell walls in mammalian and fungal. thus, which characterized by strong antibacterial activity and small adverse reactions are widely applied and practical^{3,4}. Nowadays, β -lactam antibiotics is the largest variety of antibiotics currently and play a critical role in the treating infection diseases⁵. However, the overuse of antibiotics aggravated the emerging of antibiotic-resistant pathogens, making the original effective antibiotics lose their effect. The treatment of bacterial infections has faced with a new challenge, because of the emergency of bacterial multidrug-resistant and pan-drug resistance⁶⁻⁸. One of the effective ways to problem-solving of bacterial resistance is to introduce novel structural group different from previous and develop new antibacterial drugs.

Cephalosporin antibiotics, which were developed in the late 1960s, a class of atypical semisynthetic β -lactam antibiotics⁹. Because of their broad-spectrum, strong antibacterial activities, resistance to β -lactamase, low toxicity and less allergic reactions, cephalosporin have a variety of advantages and play an important role in the treatment of severe infection in hospitals¹⁰. Currently, more than 60 cephalosporin antibiotics have been put on the market and they have made great contributions to treat bacterial infections¹¹. However, with the widespread use of cephalosporin, the bacterial drug resistance has increased and became the most important problem are similar to those of other β -lactam antibiotics^{12,13}. There is an urgent need to find new cephalosporin antibiotics with novel structures, long half-life, less side effects and more potent activities¹⁴.

In previous studies, carbapenem are β -lactam antibiotics that have a (3S)-pyrrolidine-3-ylthio moiety side chain, when a sulfonamide or sulfamoylamino group was introduced to 5-position of pyrrolidine, a significant change in antibacterial activity was available¹⁵⁻¹⁹. As shown in Fig. 1, compound 2 contain a sulfonamide moiety compared to compound 1 (meropenem), the antibacterial activity of compound 2 is almost the same as that of compound 1 but the stability to DHP-1 superior to meropenem²⁰. While compound 3 has a sulfamoylamino structure and the antibacterial activity against Gram-positive bacteria surpassed that of meropenem and displayed better stability²¹ to DHP-1. A similar structure was introduced to compound 4, exhibited better antibacterial




Fig. 1: Carbapenem analogues 1-4

activity against Gram-positive and Gram-negative bacteria than meropenem and the stability to DHP-I is significantly higher²².

So, in this study, a series cephalosporin analogue with (3S)-pyrrolidine-3-ylthio moiety was designed and synthesized and the antibacterial activity of these analogues by introducing a sulfamoylamino group to 5-position of pyrrolidine was evaluated. The aim is to display the relation between the structure and antibacterial properties and further to discover novel antibacterial potential compounds.

MATERIALS AND METHODS

All of solvents and reagents used in experiments come from commercial sources such as Macklin (www.macklin.cn), Adamas-beta (www.adamas-beta.com) and Aladdin (www.aladdin-reagent.com) used without further purification. These cephalosporin analogues were synthesized at Synthesis Lab from October, 2018-July, 2019 and the antibacterial activity was determined at Microbiology Lab in September, 2019.

Synthesized the cephalosporin analogues: The synthesis of cephalosporin analogues by chemical method, according to specific reaction conditions and measured the chemical structure by ¹H-NMR and LC-MS.

Evaluation of the antibacterial activity: The antibacterial activity of cephalosporin analogues was determined using experimental disc diffusion method²³. The compound dissolve and dilute to 250 $\mu\text{g mL}^{-1}$ with sterile water and then double dilution in order. Six strains of Gram-positive and Gram-negative bacteria were inoculated in broth at 37°C and cultured overnight. Quantify with a multi-point inoculators and inoculated 10^5 CFU/point and then incubated at 37°C for 18 h to observe the minimum inhibitory concentration (MIC value, $\mu\text{g mL}^{-1}$).

Statistical analysis: The results were analyzed by one-way ANOVA test using SPSS 19.0 with a statistically significant were considered.

RESULTS

Synthesized the cephalosporin analogues: A series of cephalosporin analogues was synthesized. The molecular structure of these compounds is given in Fig. 2. As shown, cephalosporin analogues 5a-5e have (3S)-pyrrolidine-3-ylthio side chain and introduced a piperidine or pyrrolidine methanol moiety to 5-position of pyrrolidine. For the purpose of investigating the effect of sulfamoylamino group on antibacterial activity, the hydroxyl of 5a-5e molecular was substituted by sulfamoylamino moiety and obtained cephalosporin analogues 6a-6e for antibacterial activity test.

Antibacterial activity: The *in vitro* antibacterial activity of cephalosporin analogues was determined using experimental disc diffusion method and the results are shown in Table 1.

It could be seen from Table 1, all the samples displayed excellent antibacterial activity against the test bacteria, with Gram-positive and Gram-negative bacteria being

approximately equally susceptible. Potent antibacterial activities (generally in the range 1.56-12.5 $\mu\text{g mL}^{-1}$) were evident for hydroxyl moiety cephalosporin analogues (5a-5e) against both Gram-positive and Gram-negative bacteria. The sulfamoylamino-containing cephalosporin analogues (6a-6e) also exhibited significantly antibacterial activity (generally in the range 0.39-6.25 $\mu\text{g mL}^{-1}$) against the test bacteria. The MIC value of the tested cephalosporin analogues was slightly lower than the positive control except compound 6a and 6b exhibited the same antibacterial activity against *S. epidermidis* and *E. coli*. It is notable that there exhibits a significantly improved of antibacterial activity while hydroxyl moiety was substituted by sulfamoylamino group at the same position.




Fig. 2: Cephalosporin analogues 5a-e, 6a-e

Table 1: *In vitro* antibacterial activity ($\mu\text{g mL}^{-1}$) of the cephalosporin analogues

Compounds	<i>S. aureus</i>	<i>S. pneumonia</i>	<i>S. epidermidis</i>	<i>E. coli</i>	<i>P. aeruginosa</i>	<i>K. pneumonia</i>
5a	3.13	3.13	1.56	6.25	12.5	1.56
5b	3.13	1.56	1.56	6.25	12.5	1.56
5c	6.25	3.13	3.13	12.5	12.5	1.56
5d	6.25	6.25	6.25	12.5	12.5	1.56
5e	3.13	6.25	3.13	12.5	12.5	1.56
6a	1.56	0.78	0.78	3.13	6.25	0.39
6b	1.56	0.78	0.78	3.13	6.25	0.39
6c	1.56	1.56	1.56	6.25	6.25	0.39
6d	3.13	1.56	3.13	6.25	6.25	0.39
6e	1.56	1.56	1.56	6.25	6.25	0.78
Cefpirome	0.78	0.39	0.78	3.13	3.13	0.195

DISCUSSION

The antibacterial activity of cephalosporin analogues 5a-5e, 6a-6e and positive control both displayed excellent antibacterial activity against the test Gram-positive and Gram-negative bacteria and the antibacterial activity of 6a-6e was significantly superior to 5a-5e since hydroxyl moiety was substituted by sulfamoylamino group. It indicated that have a positive effect of antibacterial activity of cephalosporin by introducing a sulfamoylamino group to molecular structure. As in previous reports, Shin *et al.*²⁰ found that sulfonamide moiety was introduced to molecular structure got a methyl-substituted carbapenem compound, exhibited better stability to DHP-1. Researchers recorded sulfamoylamino moiety was introduced to molecular structure got new carbapenem compound, displayed better antibacterial activity and the stability to DHP-1 is significantly higher better. It showed the possibility that sulfamoylamino moiety may be beneficial for the antibacterial activity of antibiotics^{21,22}. Previous assertion by Zhao *et al.*²⁴ and Badampudi *et al.*²⁵ revealed that sulfamoylamino moiety was introduced to molecular structure got the improved antibacterial activity. New research has provided more evidence, Kumar *et al.*²⁶ and Elgemeie *et al.*²⁷ also affirmed that the structure-activity relationship between sulfamoylamino structure and antibacterial activity, introduction of a sulfamoylamino group provided compounds with significantly improved antibacterial activity.

Although its mechanism of action is not clear, one possible reason is that sulfamoylamino have stronger cohesion with bacterial protein than hydroxyl and form stronger hydrogen bonds which provided stronger antibacterial activity. The antibacterial activity of 6a-6e slightly below the positive control at most test bacteria, it can be speculated that a larger molecular backbone causes partially offset the binding force. It is obvious that introduction of sulfamoylamino groups to compound lead to the improvement of antibacterial activity.

The results provided us strong evidence to further understand the structure-activity relationship cephalosporin and valuable information to find new cephalosporin antibiotics with novel structures and activities that are more potent.

CONCLUSION

The screening result discovered that the sulfamoylamino was introduced to 5 -position of pyrrolidine of cephalosporin were able to significantly improved the antibacterial activity against the test bacteria, compared with hydroxyl

cephalosporin analogues. It is displayed that the introduction of sulfamoylamino groups can enhance the antibacterial activity of cephalosporin analogues. The result is consistent with that of β -lactam antibiotics carbapenem as described by previous studies, indicating that sulfamoylamino groups can enhance the antibacterial activity of β -lactam antibiotics. The valuable result of this provided us an evidence for the further develop of antibacterial research and providing potential antibiotics for problem of bacterial resistance.

SIGNIFICANCE STATEMENT

This study discovered the possible interaction effect between sulfamoylamino and bacterial protein, which may be beneficial for the antibacterial activity of β -lactam antibiotics. This study will help the researcher to understand the mechanism of action of sulfamoylamino-containing β -lactam antibiotics that many researchers were not able to explore. Thus, a new theory on sulfamoylamino group was introduced to β -lactam antibiotics will able to significantly improve the antibacterial activity may be arrived at.

ACKNOWLEDGMENT

This research was supported by grants from Guangxi Natural Science Foundation Program (No. 2016GXNS FAA380118).

The author would like to thanks Karim Foundation for bearing the cost of article production, hosting as well as liaison with abstracting & indexing services, and customer services.

REFERENCES

1. Grossman, C.M., 2008. The first use of penicillin in the United States. *Ann. Internal Med.*, 149: 135-136.
2. Brown, A.G., 1987. Discovery and development of new β -lactam antibiotics. *Pure Applied Chem.*, 59: 475-484.
3. Chait, R., K. Vetsigian and R. Kishony, 2012. What counters antibiotic resistance in nature? *Nat. Chem. Biol.*, 8: 2-5.
4. D'Costa, V.M., C.E. King, L. Kalan, M. Morar and W.W. Sung *et al.*, 2011. Antibiotic resistance is ancient. *Nature*, 477: 457-461.
5. Nikaido, H., 2009. Multidrug resistance in bacteria. *Annu. Rev. Biochem.*, 78: 119-146.
6. Munita, J.M. and C.A. Arias, 2016. Mechanisms of antibiotic resistance. *Microbiol. Spectrum.*, Vol. 4, No. 2. 10.1128/microbiolspec.VMBF-0016-2015.
7. Wu, Y., 2012. The global antibiotics' market outlook. *World Notes Antibiot.*, 33: 119-124.

8. Zhao, L.M., Z.X. Liu and G.J. Zhao, 2018. Research progress of β -lactam antibiotics. *World Notes Antibiot.*, 39: 450-455.
9. Li, J.Y. and J.F. Gu, 2014. Research progress and market trend of the fifth generation cephalosporin antibiotics. *Prog. Pharmaceut. Sci.*, 38: 741-746.
10. Liu, Y.M., S.C. Du, H.S. Wang, D.D. Han and J.B. Gong, 2016. Advances in cephalosporin antibiotics solvates research. *Chin. J. Antibiot.*, 41: 161-165.
11. Chaudhry, S.B., M.P. Veve and J.L. Wagner, 2019. Cephalosporins: A focus on side chains and β -lactam cross-reactivity. *Pharmacy*, Vol. 7, No. 3. 10.3390/pharmacy7030103.
12. Pollegioni, L., E. Rosini and G. Molla, 2013. Cephalosporin C acylase: Dream and/or reality. *Applied Microbiol. Biotechnol.*, 97: 2341-2355.
13. Pollegioni, L., S. Lorenzi, E. Rosini, G.L. Marcone and G. Molla *et al.*, 2005. Evolution of an acylase active on cephalosporin C. *Protein Sci.*, 14: 3064-3076.
14. Buynak, J.D., 2004. The discovery and development of modified penicillin- and cephalosporin-derived β -lactamase inhibitors. *Curr. Med. Chem.*, 11: 1951-1964.
15. Zhang, T., M.X. Ni, L. Shao and D.J. Chen, 2015. Research progress in mechanism of β -lactam antibiotics. *Chin. J. Antibiot.*, 40: 785-790.
16. Bush, K. and P.A. Bradford, 2016. β -Lactams and β -lactamase inhibitors: An overview. *Cold Spring Harbor Perspect. Med.*, Vol. 6, No. 8. 10.1101/cshperspect.a025247.
17. Tehrani, K.H.M.E. and N.I. Martin, 2018. β -lactam/ β -lactamase inhibitor combinations: An update. *MedChemComm*, 9: 1439-1456.
18. Ambrose, P.G., O. Lomovskaya, D.C. Griffith, M.N. Dudley and B. VanScoy, 2017. β -Lactamase inhibitors: What you really need to know. *Curr. Opin. Pharmacol.*, 36: 86-93.
19. Decuyper, L., M. Jukic, I. Sosic, A. Zula, M. D'hooghe and S. Gobec, 2018. Antibacterial and β -lactamase inhibitory activity of monocyclic β -lactams. *Med. Res. Rev.*, 38: 426-503.
20. Shin, K.J., K.H. Yoo, D.J. Kim, S.W. Park and B.S. Ko *et al.*, 1998. Synthesis and biological properties of new 1 β -methylcarbapenems. *Bioorg. Med. Chem. Lett.*, 8: 1607-1612.
21. Gu, J.F. and J. Wang, 2008. Activity analysis of the novel carbapenem-doripenem. *Pharmaceut. Clin. Res.*, 16: 37-41.
22. Kim, S.H., J.W. Kwon, W.B. Kim, I. Lee and M.G. Lee, 2002. Effects of water deprivation for 72 h on the pharmacokinetics of a new carbapenem, DA-1131, in rats. *Life Sci.*, 71: 2291-2298.
23. Jiang, X., Z. Yuan, X. Yu and W. Zhou, 2014. Synthesis and antimicrobial activity of some new 1 β -methylcarbapenem derivatives having pyrrolidine or piperidine moieties. *Bulg. Chem. Commun.*, 46: 852-856.
24. Zhao, L., A. Marquis, V.D. La, M. Agamennone, F. Loiodice, P. Tortorella and D. Grenier, 2013. Effects of biphenyl sulfonylamino methyl bisphosphonic acids on *Porphyromonas gingivalis* and cytokine secretion by oral epithelial cells. *Med. Chem.*, 9: 855-860.
25. Badampudi, S.K., R.G.P. Aluru, R.R. Papammagari and R.L.R.K. Rao, 2014. Synthesis, characterization and pharmacological evaluation of certain sulfonamide containing heterocyclic motifs. *Polish Ann. Med.*, 21: 75-81.
26. Kumar, B.S., A.R.G. Prasad, P.R. Reddy and L.K. Ravindranath, 2016. Synthesis, antimicrobial and *in silico* EGFR inhibitory activity evaluation of sulfonylamino pyrrolidine derivatives. *Pharmaceut. Chem. J.*, 50: 443-450.
27. Elgemeie, G., F. Altalbawy, M. Alfaidi, R. Azab and A. Hassan, 2017. Synthesis, characterization and antimicrobial evaluation of novel 5-benzoyl-*N*-substituted amino- and 5-benzoyl-*N*-sulfonylamino-4-alkylsulfanyl-2-pyridones. *Drug Des. Dev. Ther.*, 11: 3389-3399.